Adam Kaplan
Family Medicine · Plano, TXNPI 1245322056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 400 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Novo Nordisk at 28.0% of the total. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$479
- Lilly USA, LLC$423
- Takeda Pharmaceuticals U.S.A., Inc.$383
- AbbVie$342
- Sanofi-aventis U.S. LLC$295
- plus $2K from 31 others
Across 246 payments — averaging $4970.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$726K
- Seqirus USA Inc$329K
- GSK$93K
- Hikma Pharmaceuticals USA$59K
- Cue Health Inc.$16K
- Shionogi Inc$1K
What the payments were for
- Food & beverage$5,975100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 134 | $1,678 |
| AstraZeneca | 32 | $479 |
| Lilly USA, LLC | 27 | $423 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $383 |
| AbbVie(2 entities) | 19 | $342 |
| Sanofi-aventis U.S. LLC | 19 | $295 |
| Merck | 18 | $291 |
| Boehringer Ingelheim | 18 | $291 |
| Abbott | 10 | $189 |
| Amgen(2 entities) | 12 | $185 |
| Vivus LLC | 13 | $184 |
| Pfizer | 8 | $176 |
| Currax Pharmaceuticals LLC | 12 | $170 |
| GSK | 11 | $163 |
| Eisai Inc. | 8 | $116 |
| Johnson & Johnson | 3 | $92 |
| Amarin Pharma, Inc. | 5 | $69 |
| Biohaven Pharmaceuticals, Inc. | 2 | $59 |
| Astellas Pharma US Inc | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $39 |
| Tolmar, Inc. | 2 | $37 |
| Corcept Therapeutics | 1 | $26 |
| Exact Sciences | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Biocryst US Sales Co., LLC | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$5,992 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $584 |
| Atorvastatin Calcium | 13 | $72 |
| Amlodipine Besylate | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Plano
- Mahdi AwwadPlano$34K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.